血清髓过氧化物酶在心血管疾病发生发展中的作用机制及临床意义研究进展  

Research progress on mechanism and clinical significance of myeloperoxidase in development and progression of cardiovascular diseases

作　　者：阿迪拉·吾拉穆 李小雷 马依彤[3] 阿迪拉·阿扎提[4] Adia Wuamu;LI Xiaoei;MA Yitong;Adia Azhati(Heart Center Intensive Care Unit,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China)

机构地区：[1]新疆医科大学第一附属医院心脏中心重症监护室,新疆乌鲁木齐830054 [2]湖北医药学院第二临床学院国药东风总医院心血管内科,湖北十堰442000 [3]新疆医科大学第一附属医院心脏中心,新疆乌鲁木齐830054 [4]新疆医科大学第一附属医院急救创伤中心急诊内科,新疆乌鲁木齐830054

出　　处：《山东医药》2025年第1期129-133,共5页Shandong Medical Journal

基　　金：新疆维吾尔自治区天山英才科技创新领军人才项目(2022TSYCLJ0067)。

摘　　要：血清髓过氧化物酶(MPO)是一种主要存在于中性粒细胞的促氧化酶,在单核细胞中表达较少,是髓细胞的特异性标志物。作为一种关键的炎症和氧化应激标志物,MPO在冠心病、急性冠状动脉综合征、心力衰竭、心房颤动等多种心血管疾病的发生发展中发挥重要作用,并且具有成为心血管疾病治疗靶点和风险评估生物标志物的潜力。深入了解MPO在心血管疾病中的作用机制及临床意义,可以为开发新的治疗药物和干预措施提供潜在的靶点,同时也有助于更好地理解和管理心血管疾病,从而改善患者的预后及生活质量。Serum myeloperoxidase(MPO)is a kind of prooxidase,which is mainly present in neutrophils,but is less expressed in monocytes,serving as a specific marker for myeloid cells.As a key inflammatory and oxidative stress marker,MPO plays a significant role in the development of various cardiovascular diseases(CVD),including coronary heart disease(CHD),acute coronary syndrome(ACS),heart failure(HF),and atrial fibrillation(AF).It has the potential to become a therapeutic target and risk assessment biomarker for CVD.Gaining a deeper understanding of the mechanism and clinical significance of MPO in CVD can provide potential targets for the development of new therapeutic drugs and interventions.It also helps to better understand and manage CVD,thereby improving patients´prognosis and quality of life.

关 键 词：髓过氧化物酶 心血管疾病 氧化应激 炎症反应 冠心病 急性冠状动脉综合征 

分 类 号：R543[医药卫生—心血管疾病]